Dapagliflozin-entresto protected kidney from renal hypertension via downregulating cell-stress signaling and upregulating SIRT1/PGC-1α/Mfn2-medicated mitochondrial homeostasis

被引:1
作者
Ko, Sheung-Fat [1 ]
Yang, Chih-Chao [2 ]
Sung, Pei-Hsun [3 ,4 ,5 ]
Cheng, Ben-Chung [2 ]
Shao, Pei-Lin [6 ]
Chen, Yi-Ling [3 ,4 ]
Yip, Hon-Kan [3 ,4 ,5 ,6 ,7 ,8 ]
机构
[1] Kaohsiung Chang Gung Mem Hosp, Dept Radiol, Kaohsiung 88301, Taiwan
[2] Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Div Nephrol, Kaohsiung 88301, Taiwan
[3] Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Div Cardiol, Kaohsiung 88301, Taiwan
[4] Kaohsiung Chang Gung Mem Hosp, Inst Translat Res Biomed, Kaohsiung 88301, Taiwan
[5] Kaohsiung Chang Gung Mem Hosp, Ctr Shockwave Med & Tissue Engn, Kaohsiung 88301, Taiwan
[6] Asia Univ, Dept Nursing, Taichung 41354, Taiwan
[7] China Med Univ, China Med Univ Hosp, Dept Med Res, Taichung 40402, Taiwan
[8] Chang Gung Univ, Coll Med, Sch Med, Taoyuan 33302, Taiwan
关键词
Chronic kidney disease; hypertension; renal function; dapagliflozin; entresto; kidney ultrastructure; BLOOD-PRESSURE; DISEASE; ENALAPRIL; LCZ696; DEATH;
D O I
10.1177/15353702231198087
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
This study tested whether combined dapagliflozin and entresto would be superior to mere one therapy on protecting the residual renal function and integrity of kidney parenchyma in hypertensive kidney disease (HKD) rat. In vitro results showed that the protein expressions of oxidative-stress/mitochondrial-damaged (NOX-1/NOX-2/oxidized-protein/cytosolic-cytochrome-C)/apoptotic (mitochondrial-Bax/cleaved caspeases 3, 9)/cell-stress (p-ERK/p-JNK/p-p38) biomarkers were significantly increased in H2O2-treated NRK-52E cells than those of controls that were reversed by dapagliflozin or entresto treatment. Adult-male SD rats (n = 50) were equally categorized into group 1 (sham-operated-control), group 2 (HKD by 5/6 nephrectomy + DOCA-salt/25 mg/kg/subcutaneous injection/twice weekly), group 3 (HKD + dapagliflozin/orally, 20 mg/kg/day for 4 weeks since day 7 after HKD induction), group 4 (HKD + entresto/orally, 100 mg/kg/day for 4 weeks since day 7 after HKD induction), and group 5 (HKD + dapagliflozin + entresto/the procedure and treatment strategy were identical to groups 2/3/4). By day 35, circulatory levels of blood-urine-nitrogen (BUN)/creatinine and urine protein/creatinine ratio were lowest in group 1, highest in group 2, and significantly lower in group 5 than in groups 3/4, but no difference between groups 3/4. Histopathological findings showed the kidney injury score/fibrotic area/cellular expressions of oxidative-stress/kidney-injury-molecule (8-OHdG+/KIM-1+) exhibited an identical trend, whereas the cellular expressions of podocyte components (synaptopodin/ZO-1/E-cadherin) exhibited an opposite pattern of BUN level among the groups. The protein expressions of oxidative stress/mitochondrial-damaged (NOX-1/NOX-2/oxidized protein/cytosolic-cytochrome-C/cyclophilin-D)/apoptotic (mitochondrial-Bax/cleaved-caspase 3)/mitochondrial-fission (PINK1/Parkin/p-DRP1)/autophagic (LC3BII/LC3BI ratio, Atg5/beclin-1)/MAPK-family (p-ERK/p-JNK/p-p38) biomarkers displayed a similar pattern, whereas the protein expression of mitochondria-biogenesis signaling (SIRT1/PGC-1 alpha-Mfn2/complex I-V) displayed an opposite pattern of BUN among the groups. In conclusion, combined dapagliflozin-entresto therapy offered additional benefits on protecting the residual kidney function and architectural integrity in HKD rat.
引用
收藏
页码:2421 / 2439
页数:19
相关论文
共 49 条
  • [1] Long-term renal outcome in patients with malignant hypertension: a retrospective cohort study
    Amraoui, Fouad
    Bos, Sarah
    Vogt, Liffert
    van den Born, Bert-Jan
    [J]. BMC NEPHROLOGY, 2012, 13
  • [2] Bai W, 2017, FRONT MOL NEUROSCI, V10, DOI [10.3389/fnmol.2017.00400, 10.3389/fnmol.2017.00443]
  • [3] DOCA-Salt Hypertension: an Update
    Basting, Tyler
    Lazartigues, Eric
    [J]. CURRENT HYPERTENSION REPORTS, 2017, 19 (04)
  • [4] Renal microvascular dysfunction, hypertension and CKD progression
    Bidani, Anil K.
    Polichnowski, Aaron J.
    Loutzenhiser, Rodger
    Griffin, Karen A.
    [J]. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2013, 22 (01) : 1 - 9
  • [5] Chen KH., 2017, AM J TRANSL RES, V9
  • [6] Cherney DZI., 2020, LANCET DIABET ENDOCR, V8
  • [7] Chertow GM., 2021, J AM SOC NEPHROL, V32
  • [8] Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients
    Desai, Akshay S.
    McMurray, John J. V.
    Packer, Milton
    Swedberg, Karl
    Rouleau, Jean L.
    Chen, Fabian
    Gong, Jianjian
    Rizkala, Adel R.
    Brahimi, Abdel
    Claggett, Brian
    Finn, Peter V.
    Hartley, Loren Howard
    Liu, Jiankang
    Lefkowitz, Martin
    Shi, Victor
    Zile, Michael R.
    Solomon, Scott D.
    [J]. EUROPEAN HEART JOURNAL, 2015, 36 (30) : 1990 - 1997
  • [9] Dapagliflozin: A Review in Type 2 Diabetes
    Dhillon, Sohita
    [J]. DRUGS, 2019, 79 (10) : 1135 - 1146
  • [10] Nighttime hospital blood pressure - a predictor of death, ESRD, and decline in GFR
    Drawz, Paul E.
    Rosenthal, Noah
    Babineau, Denise C.
    Rahman, Mahboob
    [J]. RENAL FAILURE, 2010, 32 (09) : 1036 - 1043